ArticleEndoscopy international open2026
Partially covered or uncovered metal stent efficacy in malignant unresectable distal biliary obstruction (METARSI): Randomized multicenter trial.
Article in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: There is no consensus regarding optimal selection of self-expandable stents (SEMS) for biliary drainage with endoscopic retrograde cholangiopancreatography (ERCP). This study compared stent dysfunction, patient survival, and adverse events in patients with unresectable malignant distal biliary strictures (DBS) treated with ERCP, randomized to partially covered (PC-SEMS) or uncovered (U-SEMS) stents. Patients and methods: A prospective, multicenter, randomized controlled trial was performed in adult patients with DBS (March 2021-February 2023) with 12-month follow-up. Analyses were conducted according to intention-to-treat (ITT) and per-protocol (PP) principles. Procedural and post-procedural outcomes were evaluated using PP analyses and stent patency was evaluated with Kaplan-Meier analysis. Results: Among 261 patients, 130 were randomized to PC-SEMS and 131 to U-SEMS. Baseline features were similar between groups (mean age 73 ± 11 years; 51% male). Most strictures were due to pancreatic adenocarcinoma (75%), and 49% of patients had metastatic disease. Overall, stent dysfunction was comparable (11% vs 14%; Conclusions: PC-SEMS and U-SEMS in unresectable DBS showed comparable patency, survival, and stent dysfunction rates, with tumor ingrowth rarely observed and a trend toward more procedure-related complications in PC-SEMS. In this group with limited survival, there was no observed patency advantage with PC-SEMS. Potential benefit of PC-SEMS in populations with longer prognosis warrants further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.